Non-small cell lung carcinoma

Researchers are testing an experimental cell therapy called HS-IT101 in people with advanced non-small cell lung cancer. The treatment uses tumor-infiltrating lymphocytes (TILs), immune cells taken from the patient's own tumor, multiplied in the lab, and given back. Before receiv…

This trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…

This phase 2 trial tests whether three cycles of the immunotherapy drug cemiplimab can cure patients with stage I non-small cell lung cancer who cannot undergo surgery or radiation. Researchers will select patients likely to respond to immunotherapy and treat them with cemiplimab…

This phase II trial tests whether giving a combination of firmonertinib, anlotinib, and chemotherapy before surgery can shrink or eliminate tumors in people with resectable EGFR-mutant non-small cell lung cancer. The study enrolls adults with stage IIA-IIIB disease who have speci…

This trial is testing a surgical technique called septum-guided segmentectomy for people with early-stage (2-3 cm) non-small cell lung cancer. The surgery aims to remove only the diseased part of the lung, guided by natural anatomical landmarks, while preserving healthy tissue. T…

This phase II trial is testing whether a novel radiation technique called spatially fractionated radiotherapy (SFRT), which delivers alternating high and low doses inside the tumor, can work together with the immunotherapy drug tislelizumab and standard chemotherapy to shrink lar…

This trial is testing whether giving a combination of iruplaltinib and pemetrexed before surgery can shrink tumors in people with early-stage ALK-positive non-small cell lung cancer. The goal is to see if this pre-treatment improves the chance of removing all cancer during surger…

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

This phase 2 trial is testing whether a three-pronged approach—tumor ablation, immunotherapy (tislelizumab), and chemotherapy—can improve outcomes for people with stage II-IIIB non-small cell lung cancer that can be surgically removed. The goal is to see if this combination can e…

This trial investigates whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery can completely eliminate tumors in people with early-stage non-small cell lung cancer (tumors 2 to 3.9 cm). Participants will receive three cycles of the drug combinat…

Researchers are testing whether a doctor can remotely steer a robotic bronchoscope over a 5G network to freeze small lung tumors from inside the airway. The study enrolls about 15 adults with non-small cell lung cancer or controlled metastatic lung tumors, each no larger than 3 c…

Researchers are testing whether adding the experimental drug RC148 to platinum-based chemotherapy helps people with advanced non-squamous non-small cell lung cancer live longer without their disease worsening, compared with tislelizumab plus the same chemotherapy. The trial enrol…

Researchers are testing whether giving targeted therapy before and after surgery helps people with stage III non-small cell lung cancer that has specific rare gene changes. The study includes 190 adults whose tumors have alterations in genes like EGFR, ALK, ROS1, MET, RET, or KRA…

Researchers are testing whether combining BL-B01D1, an experimental antibody-drug conjugate, with glecirasib, a targeted KRAS G12C inhibitor, can shrink tumors in adults with locally advanced or metastatic non-small cell lung cancer that carries a KRAS G12C mutation. The phase 2 …

Researchers are testing whether a shared checklist used during lung cancer surgery helps surgeons achieve cleaner, more complete tumor removal. The trial enrolls adults with early-stage non-small cell lung cancer who are scheduled for surgery. Half the participating hospitals use…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

Researchers are testing whether adding the immunotherapy adebrelimab to HS-20093 (risvutatug rezetecan) works better than HS-20093 alone in adults with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated and has no actionable gene changes.…

Researchers are testing whether adding the experimental oral drug HS-10370 to platinum-based chemotherapy, with or without the immunotherapy adebrelimab, works better than tislelizumab plus chemotherapy. The trial enrolls about 448 adults with previously untreated, locally advanc…

Researchers are testing whether adding focused radiation to the few remaining cancer spots helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their disease getting worse. Participants first receive a third-generation EGFR-targeted drug plus plat…

Researchers are testing whether an experimental drug called telisotuzumab adizutecan works better than standard chemotherapy for people with non-squamous non-small cell lung cancer that has grown after earlier treatment. The trial enrolls about 660 participants whose tumors are E…

This trial tests an experimental drug called TUB-040 in adults with advanced non-small cell lung cancer that cannot be removed with surgery or has spread. TUB-040 is designed to attach to a protein on cancer cells and deliver a toxic payload directly to the tumor, potentially kil…

Researchers are studying the safety of selpercatinib, an oral drug, in people in India with advanced cancers that have changes in the RET gene. The trial includes adults with RET fusion-positive non-small cell lung cancer and adults and children aged 12 and older with RET-mutant …

Researchers are testing whether giving toripalimab plus sacituzumab tirumotecan before surgery helps people with resectable non-small cell lung cancer. The trial enrolls about 30 adults with stage II to IIIB disease that has not been treated and lacks certain driver mutations. Pa…

Researchers are comparing an experimental oral drug called JYP0322 with crizotinib in adults who have not yet received treatment for ROS1-positive locally advanced or metastatic non-small cell lung cancer. The phase III trial aims to see which drug keeps cancer from worsening lon…

Researchers are testing whether adding stereotactic radiation to two drugs, envafolimab and endostar, helps people with stage IV non-small cell lung cancer. Participants have tumors without common EGFR, ALK, or ROS1 mutations and have not received prior systemic treatment. Everyo…

This study tests whether giving high-precision radiation (SBRT) to the main tumor and nearby lymph nodes, along with standard chemotherapy, can better control stage III non-small cell lung cancer. The trial will enroll 20 adults whose tumors are less than 6 cm and who have not sp…

This trial tests a device that uses pulsed electric fields to destroy lung tumors. It is for people with early-stage non-small cell lung cancer or lung metastases that cannot be removed with surgery or treated with radiotherapy. Participants receive the ablation under general ane…

Researchers are testing a new drug called TS-104 in adults with advanced solid tumors, including lung, head and neck, ovarian, endometrial, esophageal, and gastric cancers. TS-104 is a peptide drug conjugate: it uses a targeting peptide to carry the chemotherapy drug MMAE directl…

Researchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …

This early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…

This early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This phase 2 trial tests whether zipalertinib, an oral drug that targets cancer cells with atypical EGFR mutations, can eliminate remaining cancer cells in people with early-stage non-small cell lung cancer. Participants who have completed standard treatment and show signs of min…

This trial tests whether a wireless wearable monitor (chest patch or wristband) plus a smartphone-based rehab program can help people recover lung function after surgery for non-small cell lung cancer. Participants who have had curative-intent surgery will either receive standard…

This phase 1 trial tests whether combining an experimental oral drug, JIN-A02, with an existing intravenous drug, amivantamab, is safe and can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer that has progressed after treatment with a third-generation …

This study tests whether adding a cancer vaccine (CIMAVAX-EGF) to standard targeted drugs (sotorasib or adagrasib) can help control advanced lung cancer with a KRAS G12C mutation. About 29 adults with stage III or IV non-small cell lung cancer will receive the combination. The go…

This trial tests whether a digital rehabilitation program, combined with wireless wearable monitors, can help people recover faster between two planned lung cancer surgeries. Participants with multiple primary non-small cell lung cancer will be randomly assigned to either standar…

This trial tests a type of radiation called brain-avoidant proton craniospinal irradiation (BRAVO-pCSI) in people with leptomeningeal metastases, a condition where cancer spreads to the fluid and lining around the brain and spinal cord. The study includes adults with breast cance…

This early-phase trial tests whether a special MRI scan using hyperpolarized xenon gas can help doctors plan radiation treatment for non-small cell lung cancer. The goal is to deliver enough radiation to the tumor while avoiding healthy lung tissue, which could reduce side effect…

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This phase II trial tests whether combining the antibody-drug conjugate sacituzumab tirumotecan (SKB264) with brain radiotherapy can control brain tumors in people with advanced EGFR-mutant non-small cell lung cancer. Participants have brain metastases that progressed after first…

This early study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced lung and colorectal cancers. About 20 adults will receive NK cell infusions alongside their usual drugs. The main goal is to check for side effec…

This trial is investigating whether a new combination of drugs—BL-B01D1 plus a PD-1/VEGF bispecific antibody—can work better than the current standard treatment (tislelizumab plus chemotherapy) for people with locally advanced or metastatic non-squamous non-small cell lung cancer…

This early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …

This trial tests whether a structured exercise program can strengthen the immune system's attack on non-small cell lung cancer. Patients receiving chemo-immunotherapy before surgery will either follow an exercise plan with a stationary bike or receive standard recommendations. Th…

This phase 3 trial compares two surgical approaches for early-stage non-small cell lung cancer with small (≤2 cm), solid-dominant tumors located deep within the lung. One group receives segmentectomy, which removes only the affected segment of the lung, while the other receives l…

This phase II trial is testing whether combining two targeted drugs—andamertinib and anlotinib—can help people with advanced non-small cell lung cancer whose tumors have grown despite prior treatment with a third-generation EGFR inhibitor. The study enrolls adults with locally ad…

This phase 3 trial tests whether adding an experimental drug called izalontamab brengitecan to the standard targeted therapy osimertinib works better than osimertinib alone or with chemotherapy for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior…

This phase II trial is testing whether combining trastuzumab rezetecan, a targeted antibody-drug therapy, with radiotherapy can help people with HER2-mutated advanced non-small cell lung cancer whose disease has started to grow again after initial treatment. The study will enroll…

This trial tests whether tirzepatide, a medication used for weight management, can reduce the rapid weight gain and metabolic changes caused by lorlatinib, a targeted therapy for ALK-positive non-small cell lung cancer. Adults already taking lorlatinib will receive weekly tirzepa…

This phase II trial is testing whether giving the chemotherapy drug thiotepa directly into the spinal fluid—via a small device called an Ommaya reservoir—can help control cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases) in people with …

This trial is testing whether combining two drugs—an immunotherapy called adebrelimab and a targeted therapy called trastuzumab rezetecan—can shrink tumors in people with stage III HER2-positive lung cancer that cannot be removed surgically. Participants receive several cycles of…

This phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…

This trial is testing two different radiation schedules for people with peripheral lung cancer or a single lung metastasis. One group receives the standard five-session treatment, while the other gets an experimental three-session approach. The goal is to see if the shorter sched…

This trial tests whether combining an EGFR-targeted pill (EGFR-TKI) with an antibody-drug conjugate (trastuzumab rezetecan) can shrink tumors in people with advanced non-small cell lung cancer that has both an EGFR mutation and HER2 alterations. Participants receive the combinati…

This pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…

This study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few resistant spots in metastatic lung cancer patients who are already on targeted therapy (TKI). About 60 adults with EGFR or ALK mutations will receive radiation to those spots, and do…

This trial is testing whether a blood test that detects cancer DNA can guide the use of durvalumab, an immunotherapy, after standard chemoradiotherapy in patients with stage III lung cancer that cannot be removed by surgery. The goal is to see if giving durvalumab only to patient…

This study tests whether a fecal microbiota transplant (FMT) — transferring healthy gut bacteria from a donor — can help restore the immune system's ability to fight advanced non-small cell lung cancer in 15 patients whose disease worsened after prior immunotherapy. Participants …

This phase 3 trial is testing whether an investigational drug called ABBV-1480, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced or metastatic squamous non-small cell lung cancer. Particip…

This study is for people with advanced non-small cell lung cancer who also have interstitial lung disease (ILD), a condition that causes lung scarring. Many doctors avoid treating these patients due to risks of worsening ILD. The trial will test a specific chemotherapy as first t…

This trial is testing whether an experimental oral drug, HS-10504, can slow the progression of advanced non-small cell lung cancer in people whose tumors carry a specific EGFR C797S mutation and have already failed prior EGFR inhibitor therapy. Participants will be randomly assig…

This trial is testing an experimental drug called AMT-116 in people with advanced or metastatic non-squamous non-small cell lung cancer that has worsened after standard treatments. The study has two parts: the first compares two different doses of AMT-116 to see which works bette…

This phase 2 trial tests whether the immunotherapy drug cemiplimab can be used alone before surgery for certain patients with early-stage non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if some patients can safely skip chemotherapy and its harsh side ef…

This trial is testing whether combining two targeted therapies—lorlatinib and sacituzumab tirumotecan—can better control advanced ALK-positive non-small cell lung cancer when used as the first treatment. The study involves about 153 adults with locally advanced or metastatic dise…

This trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…

This phase II trial is testing whether combining an experimental drug called ALK201 with an existing immunotherapy, ivonescimab, can help people with advanced squamous non-small cell lung cancer. The study includes adults whose tumors have a specific marker (FGFR2b) and who have …

This trial tests whether a minimally invasive procedure called bronchoscopic microwave ablation can be as effective as surgery for early-stage lung cancer (stage IA). The procedure uses a bronchoscope to guide a needle to the tumor and destroy it with heat, potentially preserving…

This trial is testing an experimental drug called DS-3939a in adults with advanced solid tumors, including a type of lung cancer. The study has two parts: the first checks safety and the best dose, and the second looks at whether the drug, alone or with other cancer treatments, c…

This trial is testing whether giving radiotherapy to the main lung tumour, in addition to standard chemotherapy or immunotherapy, can reduce cancer spread and help people with metastatic non-small-cell lung cancer live longer. Around 420 adults with newly diagnosed stage IV lung …

This trial compares two treatments for early-stage lung cancer in patients who cannot have surgery: microwave ablation delivered through a bronchoscope versus standard stereotactic body radiotherapy. The goal is to see which approach better controls the tumor over two years, with…

This phase 3 trial investigates whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with a specific type of advanced lung cancer live longer without the disease worsening. Participants have non-small cell lung cancer that has spread, sho…

This study tests whether a blood test can identify people with advanced lung cancer who can be treated with immunotherapy alone instead of chemotherapy plus immunotherapy. The trial enrolls 275 adults with high PD-L1 levels and a low inflammation blood score. The goal is to see i…

This early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…

This trial investigates whether combining two drugs—JS212 (given by IV) and JS111 (taken orally)—can safely and effectively shrink tumors in people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 20 participants who have not had prior treatment f…

This study is for people with a specific type of lung cancer (EGFR-positive adenocarcinoma) that has spread to the lining of the chest, causing fluid buildup. Researchers are testing whether combining a daily targeted pill (furmonertinib) with focused chest radiation can safely c…

This phase 2 trial tests whether adding an experimental drug called ABSK043 to the standard targeted therapy osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated, PD-L1 positive). The study enrolls adults whose cancer has spread or cannot be surg…

This trial investigates a personalized approach for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior treatment. Participants first take the targeted pill befotertinib for three weeks, then a blood test checks for minimal residual disease (MRD). T…

This phase II trial tests the drug cemiplimab, an immunotherapy, given before and after surgery for people with early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. About 33 participants will receive cemiplimab for three cycles, then undergo surg…

This phase II trial investigates whether combining the immunotherapy adebelizumab with other anti-tumor drugs, given before and after surgery, can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls adults aged 18-70 with stage II or IIIA dis…

This study tests an experimental drug called HSK41959, taken as a tablet, in combination with standard cancer treatments for people with advanced solid tumors that lack a gene called MTAP. The trial includes patients with non-small cell lung cancer, pancreatic cancer, and other a…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This trial tests a combination of two drugs—tislelizumab and SYS6010—in people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after immunotherapy. Tislelizumab is an approved immunotherapy, and SYS6010 is an experimental drug that targets EGFR on can…

This study tests a new drug called XTX501 in people with metastatic non-small cell lung cancer (NSCLC) or other advanced solid tumors. The goal is to see if the drug is safe and can shrink tumors. Participants receive XTX501 alone, and researchers monitor side effects and how wel…

This study looks at how well third-generation EGFR-targeted drugs work as follow-up treatment after surgery for people with early-stage non-small cell lung cancer that has certain high-risk features. Researchers will observe about 500 patients in China who have EGFR mutations and…

This study tests a personalized cancer vaccine, made specifically for each patient, to see if it is safe and can help prevent non-small cell lung cancer from coming back after surgery. The vaccine is given alone or together with an immunotherapy drug called toripalimab. The trial…

This study investigates a drug called sacituzumab govitecan, which targets the TROP2 protein, in people with advanced non-small cell lung cancer that has stopped responding to standard EGFR-targeted treatments. Researchers are also comparing two types of PET/CT scans—one standard…

This study tests whether recakimab, an injectable drug that lowers cholesterol, can safely reduce high cholesterol caused by the lung cancer medication lorlatinib. The trial enrolls about 29 adults with advanced ALK-positive non-small cell lung cancer who developed high cholester…

This pilot study tests whether an inhaled drug called cromolyn sodium, already used for asthma, is safe and feasible for people with locally advanced lung cancer. The drug works by calming mast cells, which may play a role in tumor growth and treatment resistance. About 5 to 10 p…

This study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula o…

This study looks at the best way to manage high cholesterol caused by the targeted therapy lorlatinib in people with advanced ALK-positive non-small cell lung cancer. Some participants receive standard cholesterol-lowering drugs, while others get a more intensive combination. The…

This clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study…

This phase II trial tests a special type of radiation called lattice radiation therapy (LRT) combined with standard chemoimmunotherapy for people with stage III lung cancer that did not shrink enough after initial treatment. The LRT delivers high-dose radiation to specific spots …

This phase 4 trial tests whether combining two oral drugs—ensartinib and anlotinib—can shrink tumors or slow disease in people with ALK-positive non-small cell lung cancer that has become resistant to lorlatinib. About 80 adults with advanced (stage IIIB-IV) cancer will receive t…

This Phase 3 trial tests whether adding the experimental drug SYS6010 to standard immunotherapy can better prevent lung cancer from returning after surgery. About 570 adults with stage II-IIIB non-small cell lung cancer who did not respond well to pre-surgery treatment will be ra…

This phase 2 trial tests the drug trastuzumab deruxtecan (T-DXd) in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has high levels of the HER2 protein. Participants receive T-DXd by IV every three weeks. The study measures how long the cancer stays und…

This Phase 2 trial is testing a drug called firmonertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study uses a blood test (ctDNA) to decide if treatment should be adjusted over time. About 154 participants will receiv…

This early-phase study tests an oral drug called SNH-118110 in 240 adults with advanced solid tumors that have a specific genetic change (RET). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have tried other treatm…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests a new drug combination (SYS6010 plus enlonstobart) against the usual immunotherapy with chemotherapy for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). About 500 adults aged 18-75 who have not had prior treatment for their…

This Phase 2 trial tests whether adding two drugs (benmelstobart and anlotinib) to standard chemotherapy before chemoradiation helps people with stage III lung cancer that cannot be removed by surgery. 152 participants will be randomly assigned to receive either the new induction…

This Phase 2 trial tests whether adding the antihistamine diphenhydramine to the immunotherapy drug toripalimab and standard chemotherapy helps shrink tumors more effectively in people with operable non-small cell lung cancer. About 120 participants will receive either the combin…

This study tests whether giving a Pfizer-BioNTech COVID-19 mRNA vaccine before standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes for people with stage 4 non-small cell lung cancer. Researchers will enroll 500 adults to see if the vaccine helps the immun…

This trial tests whether an intelligent breathing exercise device helps people recover lung function after surgery for non-small cell lung cancer. Participants use the device for breathing exercises twice daily for 30 days after surgery, while a comparison group receives standard…

This pilot study tests whether an inhaled drug called AER101 can reduce glycolysis—the process cancer cells use to break down sugar for energy—in early-stage non-small cell lung cancer. Participants inhale the drug three times daily for two weeks before their scheduled surgery. T…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This phase 2 trial tests two different immunotherapy drug combinations (durvalumab with monalizumab or oleclumab) followed by personalized radiation for people with advanced non-small cell lung cancer that has a high PD-L1 score. The goal is to see which combination works better …

This Phase II trial tests a combination of two drugs, trastuzumab rezetecan and ivonescimab, in 30 people with advanced non-small cell lung cancer that has HER2 gene abnormalities. The goal is to see if the combo can control the cancer and delay progression. Participants must hav…

This study tests two treatment plans for people with lung cancer that has spread to the brain but is not causing major symptoms. One group gets focused radiation to all brain tumors first, then a new immunotherapy drug (ivonescimab) plus chemotherapy. The other group gets the imm…

This early-phase study tests two drugs together—navlimetostat and pumitamig—in people with advanced non-small cell lung cancer that has a specific genetic change (MTAP-deficient). The main goal is to find a safe dose and see if the combination helps shrink tumors. About 17 adults…

This study tests a new combination of two drugs (becotatug vedotin and pucotenlimab), with or without radiation, as a first treatment for people with advanced non-small cell lung cancer that has a specific protein (EGFR) on its surface. About 39 participants will receive the drug…

This phase 2 trial tests whether adding intermittent hypoxic training (IHT) – short sessions of breathing low-oxygen air – to standard chemo-immunotherapy can improve outcomes for people with stage II-IIIA lung squamous cell carcinoma. About 60 participants will receive either st…

This study tests whether taking only a few lymph node samples (selective sampling) works as well as removing all nearby lymph nodes (systematic dissection) in people with stage IIA-IIIB non-small cell lung cancer. All participants will first receive chemotherapy combined with imm…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This phase II trial is testing whether the targeted therapy firmonertinib, taken as a pill for 8 to 16 weeks before surgery, can shrink tumors in people with stage II-IIIB EGFR-mutated lung adenocarcinoma. About 60 participants will receive the drug and then undergo surgery to re…

This phase II trial tests an immunotherapy drug called SHR-1701 combined with chemotherapy and radiation for people with unresectable stage III non-small cell lung cancer. The study will enroll 84 participants and compare giving SHR-1701 before or after standard chemoradiation. T…

This study tests whether adding a special type of radiation (SF-SBRT) to the usual combination of immunotherapy (toripalimab) and chemotherapy helps people with stage II-III non-small cell lung cancer live longer without the cancer coming back. About 200 participants will be rand…

This study tests a new drug combination (IBI3005) in about 282 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors. Participants will be closely monitored for side effects a…

This study tests a new drug called SCTB41 combined with the chemotherapy docetaxel in 90 people with advanced non-small cell lung cancer that has worsened after prior treatment. The goal is to see if the combination is safe and works better than docetaxel alone. Participants will…

This study tests a new drug called ALK202 combined with other medicines for people with advanced non-small cell lung cancer. The trial will include 252 participants and aims to see if the combinations are safe and can shrink tumors. It is divided into two phases: first to find th…

This Phase 3 trial tests a new drug called HRS-7058 against other KRAS G12C inhibitors in 450 adults with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has stopped responding to standard treatments. The study compares how well HRS-70…

This study tests whether giving sintilimab (an immunotherapy drug) together with chemotherapy can shrink advanced stage IIIC lung cancer enough to allow surgery. About 33 adults with previously untreated, unresectable non-small cell lung cancer will receive four cycles of the com…

This study tests an oral chemotherapy (paclitaxel) combined with immunotherapy given before surgery in patients aged 70-85 with non-small cell lung cancer. The goal is to see if this approach can shrink tumors enough to improve surgery outcomes and long-term survival. About 75 pa…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This Phase 3 trial tests whether adding an experimental drug called SYS6010 to the standard treatment osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer getting worse. About 680 participants will be random…

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve…

This early-phase study tests a new drug, CS08399, in people with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goal is to find a safe dose and understand how the drug works in the body. About 186 participants will take part, and researchers…

This study tests whether adding alpha lipoic acid (a strong antioxidant) to standard chemotherapy helps people with advanced non-small cell lung cancer. About 60 adults with stage III or IV lung cancer will take 600 mg of alpha lipoic acid daily alongside their chemo. Researchers…

This phase 2 trial tests whether giving alectinib (a targeted pill) along with standard chemotherapy can shrink unresectable stage III ALK-positive lung cancer enough to allow surgery or radiation. About 50 people who have not had prior treatment will receive three cycles of the …

This phase 2 trial tests whether fecal transplants from immunotherapy responders can improve outcomes in stage II-III non-small cell lung cancer. 68 patients will receive either standard treatment (Durvalumab + chemotherapy) or the same plus fecal transplant capsules. The main go…

This phase 2 study tests whether adding a PCSK-9 inhibitor (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 participants will receive either adebrelimab or retlirafusp alfa…

This phase 2 trial tests whether combining the immunotherapy drug tislelizumab with standard chemotherapy and a targeted chemo-blocking procedure (BACE) can shrink advanced, inoperable stage III non-small cell lung cancer enough to allow surgery. About 39 participants will receiv…

This study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with a large, advanced type of lung cancer (stage III NSCLC) live longer without the cancer growing. About 204 adults aged 18-75 with tumors at least 5 cm wide or lymph nodes at least …

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This phase 2 trial tests a new drug called vebreltinib combined with standard chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has MET overexpression and no other known genetic drivers. The study will enroll 19 participants to see if the …

This phase 2 trial tests whether adding an experimental immunotherapy (iparomlimab and tuvonralimab) to targeted radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 people with stage I-IIB disease will receive the drug every 3 weeks for a year, star…

This Phase 2 trial tests a new drug called GFH375, alone or combined with other drugs (cetuximab or pemetrexed), as a first treatment for advanced non-small cell lung cancer with a specific KRAS G12D mutation. The study will enroll 90 people who have not had prior treatment. The …

This phase 2 trial tests whether adding the experimental drug rilapentib alpha to standard chemotherapy can improve outcomes for people with stage II-III non-small cell lung cancer that does not have certain gene mutations. Participants will receive the drug combination before su…

This phase 2 trial tests a combination of the drug zorifertinib plus chemotherapy delivered directly into the fluid around the brain and spine. It is for people with a specific type of lung cancer (NSCLC with EGFR mutation) whose cancer has spread to the lining of the brain and s…

This phase 2 trial tests whether combining SKB264 (a chemotherapy) with anlotinib (a targeted therapy) can shrink tumors and control disease in people with advanced non-small cell lung cancer that has spread to the liver and stopped responding to standard EGFR-targeted drugs. Abo…

This early-phase study tests an experimental oral drug called KQB368 in 48 adults with advanced solid tumors (like lung, colorectal, or uterine cancer) that have a specific KRAS mutation (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors.…

This study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for people with a specific type of advanced lung cancer (stage III-N2b non-small cell lung cancer). The goal is to see if this treatment can completel…

This early-phase trial tests whether adding BLEX 404, a liquid extract from maitake mushrooms, to standard chemotherapy (pemetrexed + cisplatin) can help people with advanced non-small cell lung cancer that has no EGFR mutation. The study will enroll 32 adults aged 20–70 who have…

This study tests a device that uses both cold and radiofrequency to treat lung tumors during a standard bronchoscopy. Twenty people with early-stage lung cancer will receive the treatment before surgical removal of the tumor. The goal is to see if the device can safely and effect…

This early-phase study tests whether giving a small, focused dose of radiation to the center of a lung tumor can safely 'prime' the immune system before standard chemoradiation and immunotherapy. About 24 adults with stage III non-small cell lung cancer that cannot be removed by …

This study tests whether combining a targeted drug (furmonertinib) with local treatments like ablation or radiation can help control early-stage non-small cell lung cancer in people who cannot or choose not to have surgery. About 45 participants with specific EGFR gene mutations …

This study looks at how safe and effective the drug SHR-A1811 is for Chinese patients with advanced or spreading non-small cell lung cancer that has a specific genetic change called HER2 alteration. About 1,000 adults will be followed as they receive the drug as part of their nor…

This Phase 2 trial tests two drug combinations for people with a specific genetic mutation (EGFR) in advanced non-small cell lung cancer. One group receives amivantamab plus lazertinib as first treatment; the other gets amivantamab plus chemotherapy after previous treatment stopp…

This study tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, in 50 people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if the treatment can shrink tumors enough to allow surgery, and to measure how long t…

This study tests a new treatment called Y-90 FAPI for people with advanced non-small cell lung cancer that has stopped responding to standard therapies. The treatment delivers radiation directly to cancer cells by targeting a protein found on tumor-supporting cells. The goal is t…

This early-stage trial will test whether infusing a patient's own tumor-fighting immune cells (called TILs) is safe for people with early-stage non-small cell lung cancer that has multiple spots in the lungs. Researchers will collect immune cells from the tumor or lung fluid, gro…

This early-phase trial tests whether combining a patient's own immune cells (called TILs) with a targeted therapy drug can safely treat advanced lung cancer that has stopped responding to standard targeted treatment. Researchers will enroll 50 adults with EGFR-mutant non-small ce…

This early-stage trial tests injecting the chemotherapy drug cisplatin directly into lung tumors using a thin tube with a camera. The goal is to see if this approach is safe and can kill more cancer cells while causing fewer side effects than standard IV chemo. The study will enr…

This phase II trial tests whether combining two drugs—sacituzumab tirumotecan and toripalimab—given before surgery can shrink tumors in people with stage II to IIIB non-small cell lung cancer (NSCLC). About 38 participants will receive the drugs intravenously over several weeks, …

This study tests a new drug combination (JSKN016, toripalimab, and carboplatin) given before surgery to people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the treatment can completely or mostly eliminate the tumor before the operatio…

This study tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer whose disease has worsened after initial treatment. About 53 adults with EGFR-mutant NSCLC and additional PIK3CA/AKT1/PTEN gene changes will receive the two dr…

This study tests two drugs together for people with advanced non-small cell lung cancer that has HER2 abnormalities. The drugs are SHR-A1811, which targets HER2, and ivonescimab, which boosts the immune system. The goal is to see if the combination can control the cancer longer. …

This early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…

This study tests a combination of the targeted drug limertinib plus chemotherapy (etoposide and carboplatin) in 30 people with a specific type of lung cancer. These patients have a mutation in the EGFR gene and their cancer has changed from non-small cell to small cell lung cance…

This phase 2 trial tests a sequence of targeted therapy (garsorasib), immunotherapy (ivonescimab), and chemotherapy before and after surgery for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed. The goal is to see if this approach increases the …

This early-phase study tests a new drug called SYS6090 combined with standard chemotherapy or other drugs in about 600 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combinations are safe and if they can shrink tumors. The trial is not …

This Phase 2 trial tests a combination of two drugs, tunlametinib and cetuximab β, in 55 people with advanced non-small cell lung cancer that has a KRAS mutation and has not responded to prior treatments. The goal is to see if the combo can shrink tumors and control the disease. …

This phase 3 study tests whether a new combination of drugs (HS-20093 plus adebrelimab) works better than the standard chemotherapy docetaxel for people with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The trial plans to enroll 45…

This study compares two types of targeted therapy (first-generation vs third-generation EGFR TKIs) for people with advanced lung cancer that has a specific rare mutation called EGFR exon 19 deletion-insertion. About 94 participants will be randomly assigned to one of the two trea…

This early-stage trial tests a new gene-editing drug called EDB-102 in 15 people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard targeted therapy. The drug uses CRISPR technology to target and disable a specific cancer-caus…

This study looks at people with advanced non-small cell lung cancer that has spread to many places (more than five spots). It tests whether adding high-precision radiation to the main lung tumor, on top of standard drug therapy, helps them live longer and keeps the tumor from gro…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This Phase 3 trial compares an experimental drug called SYS6010 with the standard chemotherapy docetaxel in about 506 people with advanced non-squamous non-small cell lung cancer that has not responded to prior treatments. The study aims to see if SYS6010 can slow cancer growth o…

This study compares two treatments for high-risk patients with early-stage non-small cell lung cancer: minimally invasive surgery (wedge resection) and stereotactic body radiation therapy (SBRT). The goal is to see which approach leads to longer disease-free survival and better q…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking …

This phase 2 trial is testing whether a combination of the experimental drug QL1706, standard chemotherapy, and bevacizumab can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has specific gene changes and has stopped responding to targeted ther…

This phase 2 trial tests a new approach for advanced non-small cell lung cancer. It combines chemotherapy and immunotherapy with a special 'high-low mixed-dose' radiotherapy that gives a strong dose to large tumors and a lower dose to smaller ones. The goal is to shrink tumors fa…

This study tests a new targeted cancer pill called limertinib combined with brain radiation as a first treatment for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. The goal is to see if the combination can better control the brain tum…

This study looks at whether taking leucogen (a drug that raises white blood cell counts) from the start can prevent low white blood cells in people with RET fusion-positive non-small cell lung cancer who are taking pralsetinib. About 25 people who have not had prior treatment wil…

This early-stage trial is testing a new oral drug called HS-10504 combined with several other drugs given by IV in people with advanced non-small cell lung cancer that has worsened after previous treatment. The study will enroll about 400 participants and aims to find safe doses …

This study tests a new drug called befotertinib combined with radiation therapy for people with advanced non-small cell lung cancer that has an EGFR mutation and has spread to only a few spots. The goal is to see if this combination can delay cancer growth. About 84 participants …

This study tests a drug called IBI363 given before surgery for people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the drug helps shrink or eliminate the tumor before the operation. About 10 participants will receive IBI363, and resea…

This phase 2 trial tests whether the drug zipalertinib, given together with standard chemotherapy, can shrink tumors in people with a specific genetic type of non-small cell lung cancer before they have surgery. The study plans to enroll 16 adults with stage II to IIIB disease wh…

This study tests two drugs, sacituzumab govitecan and ivonescimab, alone or together, in people with advanced non-small cell lung cancer that has specific gene changes. The goal is to see if the combination works better than either drug alone at shrinking tumors and delaying canc…

This early-phase study tests a new drug called JSKN027 in 250 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study focuses on colorectal, lun…

This Phase 3 trial will test whether a new drug called HB0025, combined with standard chemotherapy, works better than the current treatment tislelizumab plus chemotherapy for people with advanced nonsquamous non-small cell lung cancer. About 500 participants will be randomly assi…

This study tests a new way to perform lung cancer surgery using 3D virtual reality models and a special dye that makes lung segments glow during surgery. The goal is to help surgeons remove only the diseased part of the lung more accurately. About 89 adults with early-stage non-s…

This study compares two ways of performing robotic lung surgery for early-stage non-small cell lung cancer. In one method, the surgeon controls all tools from a console (totally robotic). In the other, a bedside assistant helps with handheld staplers. The trial will measure costs…

This study tests a combination of two drugs, SHR-A1811 and pertuzumab, in people with advanced non-small cell lung cancer that has HER2 mutations or overexpression and has worsened after at least one prior treatment. The goal is to see if this combo can shrink tumors or slow dise…

This study tests whether a higher dose of furmonertinib alone works better than a standard dose combined with chemotherapy for people with a specific type of lung cancer (EGFR-mutated) that has spread to the brain. About 60 adults who have not had prior treatment will be enrolled…

This study tests whether adding the experimental drug plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-squamous lung cancer live longer. It includes about 442 adults whose cancer has worsened despite prior immunotherapy and platinum chemo. Participan…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This study tests whether a higher dose (160 mg) of the drug firmonertinib can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer whose tumors have stayed stable but not shrunk after 8 weeks on the standard 80 mg dose. About 28 adults aged 18-75 with …

This study looks at people with stage III non-small cell lung cancer who had chemotherapy plus immunotherapy before surgery, and still had cancer in their lymph nodes after the tumor was removed. Half will get standard immunotherapy alone after surgery, and the other half will ge…

This early-phase trial is for people with non-small cell lung cancer that has stopped responding to second-line treatment. Researchers will use a lab test on a patient's own tumor cells to pick the best chemotherapy drugs, then add the statin pitavastatin. The goal is to see if t…

This study tests whether giving the anesthetic lidocaine during lung cancer surgery can reduce the chance of the cancer coming back. About 1,400 patients will be randomly assigned to receive lidocaine or a placebo. They will be followed for three years to track cancer recurrence …

This early-phase trial is testing a combination of two drugs—a targeted pill (Glecirasib) and an immunotherapy infusion (Ivonescimab)—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will first find the saf…

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This study tests a combination of two drugs (Sac-TMT and a third-generation EGFR-TKI), with or without radiation, in 45 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has spread to the brain and stopped responding to previous treatment.…

This phase 2 trial tests whether adding image-guided radioactive seed implants to standard cancer therapy can slow disease progression in patients with oligoprogressive metastatic lung or colorectal cancer. About 90 adults whose cancer has started to progress in a few spots while…

This phase 2 trial tests iruplinalkib tablets as a daily treatment after surgery for people with stage IA ALK-positive non-small cell lung cancer who have high-risk factors. The goal is to see if the drug can prevent the cancer from coming back. About 28 participants will take th…

This Phase 2 study tests two oral drugs, GH21 and D-1553, in 120 adults with advanced solid tumors that have a specific mutation called KRASG12C. Participants have already tried other treatments without success. The goal is to see if the combination can shrink tumors and control …

This early-phase study tests a new treatment for people with early-stage lung cancer that can be removed by surgery. The treatment combines NK cells (a type of immune cell), an immunotherapy drug (PD-1 antibody), and standard chemotherapy given before surgery. The main goals are …

This study tests a combination of anlotinib pills and standard chemotherapy for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. About 28 adults will receive the treatment in 21-day cycles to see how long it keeps the cancer from growing and what side effects…

This phase 2 trial tests the drug golidocitinib in 16 people with advanced lung cancer who have severe blood problems caused by immunotherapy. The goal is to see if the drug can safely improve blood counts and reduce symptoms. Participants take the drug until their blood levels r…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This study tests a new drug combination (goselasib plus other drugs) as a first treatment for people with advanced or spreading non-small cell lung cancer that has a specific gene change called KRAS G12C. About 69 adults who have not had prior treatment for their advanced cancer …

This study tests two experimental drugs, ANS014004 and PLB1004, given together to people with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC). The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing, especially…

This study tests two drugs (SHR-A1811 and adebelimumab) given before surgery to people with early-stage non-small cell lung cancer that has a specific genetic change (HER2 alteration). The goal is to see if the combination can shrink or eliminate the tumor before it is removed. A…

This trial tests a new approach for people with early-stage non-small cell lung cancer that can be removed with surgery. Before surgery, patients receive a combination of targeted radiation (SBRT), two immunotherapy drugs (iparomlimab and tuvonralimab, also called QL1706), and ch…

This Phase 2 trial tests JSKN033, a combination of two drugs (a HER2-targeted antibody-drug conjugate and a PD-L1 inhibitor), in 160 people with advanced non-small cell lung cancer that cannot be cured. The study will first find the best dose, then expand to see how well it shrin…

This study looks at people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. Some patients experience rapid tumor growth when treated with immunotherapy alone. The trial will test whether adding chemotherapy to the immunotherapy drug cemiplimab can pre…

This study tests whether adding a special type of radiation (quad shot radiotherapy) to a new immunotherapy drug (QL1706) plus chemotherapy can better control advanced non-small cell lung cancer. About 104 people with stage IV lung cancer that has not been treated yet will take p…

This study looks at whether giving pembrolizumab infusions in the morning improves outcomes for people with metastatic non-small cell lung cancer. 58 participants will be randomly assigned to morning or standard scheduling. The goal is to see if timing affects how long the cancer…

This Phase 2 trial tests whether adding SYS6010 to the standard drug osimertinib before surgery can improve outcomes for people with a specific type of lung cancer (EGFR-mutant non-squamous non-small cell lung cancer). About 120 participants with stage II-IIIB disease will receiv…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and bevacizumab—in 31 adults with advanced non-squamous lung cancer that has worsened after initial treatment. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive t…

This study tests a new targeted drug, JMKX001899, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 472 adults who have already tried at least one prior treatment will be randoml…

This Phase 2 trial tests the immunotherapy drug ivonescimab, alone or with chemotherapy, before and after surgery for people with stage II-IIIB non-small cell lung cancer that can be removed. The goal is to see if tailoring treatment based on PD-L1 levels can reduce toxicity whil…

This study tests whether the targeted drug ensartinib can help people with ALK-mutated stage III lung cancer that cannot be removed by surgery. After completing standard chemoradiotherapy, 45 participants will receive either ensartinib or a placebo to see if the drug delays cance…

This study tests a new approach for people with early-stage lung cancer who cannot or will not take chemotherapy. Before surgery, patients receive a short course of focused radiation (SBRT) combined with immunotherapy (tislelizumab) and an antiangiogenic drug (anlotinib). The goa…

This study tests an experimental pill, BPI-361175, in 30 adults with advanced non-small cell lung cancer that has specific EGFR mutations and has stopped responding to standard treatments. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors…

This study looks back at medical records of 600 Chinese patients with advanced non-small cell lung cancer that has a KRAS G12C mutation. All patients took the drug IBI351 between August 2024 and August 2025. Researchers will check how many patients' tumors shrank or disappeared, …

This study tests a new drug combination (iparomlimab and tuvonralimab) plus chemotherapy as a first treatment for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this approach can shrink tumors or delay cancer growth. About 28 adults wi…

This study looks at how well the drug taletrectinib works in people with advanced ROS1-positive non-small cell lung cancer whose cancer has gotten worse after treatment with entrectinib. Researchers will follow 50 patients in real-world clinics to see if the drug shrinks tumors a…

This study tests whether a drug called ivonescimab can help prevent lung cancer from growing back after standard chemoradiation. It involves 63 adults with stage III non-small cell lung cancer that cannot be removed by surgery. Participants will receive ivonescimab infusions for …

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This phase 2 trial tests a combination of two drugs, Sacituzumab tirumotecan and bevacizumab, in 50 people with a specific type of lung cancer (EGFR-mutant nonsquamous NSCLC) that has spread to the brain and no longer responds to standard targeted therapy. The goal is to see if t…

This phase 3 trial tests whether adding Huaier granules (a traditional Chinese medicine) to microwave ablation improves outcomes for people with stage IA non-small cell lung cancer who cannot have surgery. 180 participants will be randomly assigned to receive ablation alone or ab…

This clinical trial is testing whether giving immunotherapy a few days after chemotherapy, instead of on the same day, can improve outcomes for people with advanced non-small cell lung cancer. The study will enroll 246 adults and compare three different timing schedules, includin…

This phase II trial tests a combination of two drugs—sacituzumab tirumotecan and furmonertinib—in 45 people with advanced EGFR-mutant non-small cell lung cancer whose first targeted therapy stopped working. The study measures how many patients respond to treatment and how long th…

This Phase 3 trial compares a new drug called JYP0322 with standard platinum-based chemotherapy in 207 people with advanced ROS1-positive non-small cell lung cancer who have already been treated with ROS1-targeted therapy. The main goal is to see if JYP0322 delays cancer growth b…

This study tests whether taking two drugs—firmonertinib (a targeted pill) and bevacizumab (an infusion)—for three months before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). After surgery, patients may continue firmonertini…

This study looks at whether surgically removing the primary lung tumor before giving immunotherapy (sintilimab) and chemotherapy can improve outcomes for people with advanced non-small cell lung cancer that is not driven by EGFR or ALK mutations. About 118 participants will be ra…

This study looks at whether surgically removing the primary lung tumor before starting the targeted drug osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer. About 118 patients with stage III-IV cancer will be randomly assigned to get surgery plus osi…

This phase II trial tests whether combining cryoablation (freezing the tumor) with the immunotherapy drug serplulimab can treat early-stage non-small cell lung cancer in people who cannot have surgery or radiation. Twenty-five adults with stage Ia NSCLC will receive one cryoablat…

This phase 3 trial tests QL2107, a biosimilar (copy) of the cancer drug Keytruda, in 122 adults with non-small cell lung cancer that has been surgically removed. The goal is to see if the body processes QL2107 the same way as Keytruda when given as an extra treatment after surger…

This study tests a drug called AK112 in 60 people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has specific genetic changes and has stopped responding to previous targeted therapy. The main goal is to see how many patients' tumors shr…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests the drug Vebreltinib, taken as a pill for 8 weeks before surgery, in 30 people with stage IIA-IIIB non-small cell lung cancer that has a specific gene change (MET exon 14 skipping). The goal is to see if the drug can shrink tumors enough to improve surger…

This phase 2 trial tests whether the targeted drug bozitinib, combined with standard chemotherapy, can shrink tumors before surgery in people with stage IIA to IIIC non-small cell lung cancer that has a specific MET gene change. About 34 participants will receive the drug combo f…

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This pilot study explores whether a breath sample collected with the VosCryo device can provide enough cellular material to help diagnose advanced lung cancer. Researchers will compare breath samples from 12 people with late-stage lung cancer and 12 healthy relatives to see if th…

This study explores whether analyzing tumor DNA in cerebrospinal fluid can help doctors make better treatment decisions for people with malignant brain tumors or brain metastases from lung or breast cancer. Participants undergo a standard spinal tap or fluid collection, and the f…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study looks at whether low-dose CT scans can help find lung cancer early in people aged 40 to 80 who have never smoked. About 2,500 participants will fill out questionnaires, give blood and urine samples, and have lung function tests and CT scans. Researchers will track how …

This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…

This study compares 3D models from non-contrast CT scans to standard contrast CT scans for planning minimally invasive lung cancer surgery. Researchers will check if the 3D models accurately show blood vessels, airways, and tumor location during surgery. If they work, patients mi…

This study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …

This study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…

This study looks at whether the shingles vaccine can prevent shingles and improve survival in 500 lung cancer patients. Participants will either receive the vaccine or not, and researchers will track shingles cases and survival rates over time. The goal is to see if the vaccine o…

This early-stage trial tests whether the drug ponsegromab can help adults with advanced non-small cell lung cancer who are losing muscle mass (cachexia). About 80 participants will receive either ponsegromab or a placebo. The study measures changes in muscle size and physical fun…

This trial tests whether low-frequency repetitive transcranial magnetic stimulation (rTMS) can improve sleep quality in adults with advanced non-small cell lung cancer who have trouble sleeping during hospital stays. Researchers will randomly assign 160 participants to receive ei…

This study tests a program called LiveWell, which teaches emotional coping skills to people with metastatic lung cancer who are feeling anxious or depressed. About 80 participants will either take the program or receive usual care. The goal is to see if the program is practical, …

This study tests a LINE chatbot that gives visual, interactive tips to help lung cancer patients handle side effects from their targeted therapy. About 178 adults with advanced lung cancer will either get usual care or also access the chatbot. The goal is to see if the chatbot bo…

Shortness of breath, or dyspnea, affects most lung cancer patients and often persists despite standard treatments. This pilot study tests a stepped-care behavioral intervention called INSPIRE, which starts with brief coping skills and adds more intensive psychological support onl…

This trial compares standard radiation therapy with a new method that specifically avoids damaging small airways in the lungs. The goal is to see if this airway-sparing approach helps patients with stage III non-small cell lung cancer retain better breathing function after treatm…

This pilot study tests whether using bright light therapy for an hour each morning, delivered through an iPad app, is tolerable for people with advanced melanoma or non-small cell lung cancer who are about to start immunotherapy. The idea is that synchronizing the body's internal…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This study tests a smart breathing exercise device for people recovering from lung cancer surgery. About 200 adults will either use the device for 30 days after surgery or receive standard care. The goal is to see if the device improves lung function, reduces shortness of breath,…

This study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…

This study is testing a program called Care and Connect, where trained volunteers provide support and information to people with lung cancer. The goal is to see if this program helps reduce distress and makes it easier for patients to get the care they need. About 50 adults with …

This study tests whether a supervised exercise program, started two weeks before chemotherapy and continued for 16 weeks during treatment, can help adults aged 35 to 65 with breast, lung, or colon cancer tolerate chemotherapy better. The goal is to see if participants can receive…

This study tests whether a liquid form of megestrol acetate (a drug that stimulates appetite) can help malnourished people with non-small cell lung cancer gain weight while they receive standard chemotherapy. About 116 participants will be randomly assigned to get either the drug…

This study tests whether a supervised exercise program, done alongside chemotherapy or immunotherapy, can improve fitness and recovery in patients with locally advanced non-small cell lung cancer. 74 participants will be randomly assigned to either exercise training or usual care…

This study tests a special care plan to help Chinese patients with advanced EGFR-mutated lung cancer who are taking the drug amivantamab. The plan focuses on preventing common side effects like blood clots, skin rashes, and infusion reactions. About 122 adults will join to see if…

This study compares two types of anesthesia for early-stage lung cancer surgery: one that lets patients breathe on their own and one that uses a breathing tube. Researchers want to see which method leads to a shorter hospital stay and less pain medication use. The study will incl…

This study looks at whether a two-week program of walking and breathing exercises before surgery for non-small cell lung cancer can help reduce pain, speed up recovery, shorten hospital stays, and improve quality of life. About 62 adults scheduled for surgery will be split into t…

This early study tests whether selpercatinib, a drug already used for certain cancers, can help with cachexia (severe weight loss and appetite loss) in people with advanced lung, colon, or pancreatic cancer. Seven participants will take the drug twice daily for 12 weeks, with reg…

This study tests whether a short, intensive psychological program before lung cancer surgery can lower anxiety and depression. About 138 adults scheduled for lung cancer surgery will be split into three groups: one receiving four weekly therapy sessions, one refusing support, and…

This study tests whether a postbiotic supplement called JK-5G can help people with advanced non-small-cell lung cancer who are losing weight (cachexia). About 150 participants will take either the supplement or a placebo powder three times a day for 90 days while continuing their…

This pilot study will test whether a 6-month athletic program can improve lung function and quality of life in 10 patients who had surgery for non-small cell lung cancer. Participants will follow a supervised exercise plan and be compared to similar patients who did not exercise.…

Researchers are testing whether people with non-small cell lung cancer can collect their own small blood samples at home using a finger-prick kit. Participants receive standard treatment with docetaxel, paclitaxel, alectinib, or lorlatinib, and the samples measure how much cancer…

This study looks at how much pembrolizumab (an immunotherapy drug) remains in the blood after treatment ends and whether that affects how well chemotherapy works later. Researchers will follow 110 people with non-small cell lung cancer or head and neck cancer who have stopped pem…

Researchers are studying whether the mix of bacteria in a person's gut can predict how well they respond to immunotherapy drugs called immune checkpoint inhibitors. The trial enrolls about 360 adults with advanced non-small cell lung cancer, melanoma, endometrial cancer, or cervi…

Some people who have keyhole lung cancer surgery develop lasting breathlessness and struggle with gentle exercise, even if their breathing was fine before. Researchers suspect the right side of the heart, which pumps blood to the lungs, may be weakened by the extra pressure it fa…

This study reviews medical records of 250 people with advanced or metastatic non-small cell lung cancer that has a specific change in the EGFR gene. Researchers want to learn about patients' backgrounds, the treatments they receive, and how well those treatments work. The goal is…

This observational study follows Indian adults with resectable non-small cell lung cancer who are prescribed durvalumab as part of their routine care. The goal is to monitor how often patients experience serious side effects, including severe adverse events and other complication…

This study uses a special PET scan to track a tracer called 89Zr-trastuzumab in people with advanced lung cancer that has HER2 changes. The goal is to see if the tracer builds up differently in tumors with HER2 mutations versus those with too much HER2 protein. About 20 adults wi…

This study is exploring whether the bacteria in your gut can predict how well a certain type of lung cancer responds to treatment. Researchers are following 100 people with stage II-IIIB non-small cell lung cancer who are receiving chemoimmunotherapy before surgery. The goal is t…

This study is looking at whether analyzing blood, urine, and stool samples can help predict which lung cancer patients are more likely to develop radiation pneumonitis—a type of lung inflammation—after receiving immunotherapy and radiation therapy. The researchers will collect sa…

This study tests a new way to see where an immunotherapy drug goes in the lungs of people with stage III lung cancer. Twenty participants will receive a small dose of a fluorescent version of the drug durvalumab, then have a special camera bronchoscopy to spot the drug in tumors …

This study takes leftover tumor samples from people with EGFR-mutant non-small cell lung cancer and grows them in the lab as cell cultures and organoids. Researchers will test different anti-EGFR drugs on these models to see which ones work best for each type of mutation and expl…

This phase 1 trial investigates how HS-10504, an experimental drug for EGFR-mutant non-small cell lung cancer, changes the way the body processes midazolam, a common sedative. About 24 patients with advanced lung cancer who have stopped responding to standard EGFR-targeted therap…

This study explores whether a hair follicle or cheek swab can accurately measure a person's internal body clock (circadian rhythm) in patients with advanced lung cancer receiving immunotherapy. Researchers will use a new tool called TimeTeller to analyze gene activity from these …

This observational study looks at adults with non-small cell lung cancer that has spread to the brain. Researchers want to see if getting radiation and immunotherapy 30 days apart or closer together changes how long the brain tumors stay stable and how long patients live. Partici…

This study looks at medical records of 3,000 adults with lung cancer to see if the stage at diagnosis is shifting to earlier, more curable stages. Researchers will track how often cancer is found through screening programs, chest X-rays, or heart scans. No new treatments or tests…

This study watches how well the drug repotrectinib works and what side effects it causes in Korean patients with a specific type of lung cancer or solid tumors that have certain gene changes. About 10 patients will be followed for up to 12 months during their normal treatment. Th…

This study will look back at medical records of 300 people with advanced non-small cell lung cancer (NSCLC) whose disease got worse after first-line immunotherapy. Researchers want to see which second-line treatments were used and how well they worked in real-world practice. The …

This study tests whether a special headset (extended reality) can help surgeons plan the removal of cancer-affected lymph nodes in the neck for people with lung cancer. Ten patients will have their PET and CT scans combined into a 3D model that the surgeon views just before surge…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…

This study will collect tumor samples and medical data from 150 adults with non-small cell lung cancer (stages I to IV) at Bordeaux University Hospital. Researchers will analyze the molecular, metabolic, and immune features of the tumors to understand how the cancer progresses an…

This pilot study will check if tumor DNA in spinal fluid can predict brain metastases in 40 patients with stage III or IV non-small cell lung cancer. Participants will undergo a lumbar puncture to collect cerebrospinal fluid, plus blood draws and an MRI six months later. The goal…

This study will test a new single-port surgical robot, called SHURUI, for chest surgeries like removing lung tumors or mediastinal masses. About 40 adults aged 18-75 who need these surgeries will take part. The goal is to see if the robot is safe and works well, with hopes of les…

This study looks at sputum and blood samples from 50 adults with advanced non-small cell lung cancer who are starting immunotherapy. Researchers want to find immune cell changes that could predict which patients will respond well to treatment. The goal is to better understand the…

This study will enroll 63 people with advanced non-small cell lung cancer whose disease has been stable for at least 6 months. Participants will take part in a 3-month rehabilitation program that includes physical activity. Researchers will measure quality of life, hand grip stre…

This early study tests whether applying low-intensity electric fields (TTFields) to the chest before lung cancer surgery is safe and affects cancer-related genes. About 18 adults with stage I-IIIA non-small cell lung cancer will wear a non-invasive device for a short time before …

This study looks back at medical records of 350 people with advanced non-small cell or small cell lung cancer who took anlotinib after their previous treatment stopped working. The goal is to see how well anlotinib works and how safe it is when used in later lines of therapy. The…

This study aims to see if changes in certain immune cells in the blood can predict how well advanced lung cancer patients respond to a combination of chemotherapy and immunotherapy. About 80 adults with stage IIIB or IV non-small cell lung cancer will give blood samples before an…

This study looks at whether tiny particles in the blood, called extracellular vesicles, can help doctors predict if immunotherapy will work for people with advanced lung cancer or melanoma. Researchers will collect blood samples from 378 patients before and during standard treatm…

This study looks at the best way to use a breathing machine during lung surgery to prevent lung problems after the operation. It will involve 650 adults over 50 having lung surgery. The goal is to find which breathing settings cause the fewest lung complications like pneumonia or…

This study looks at how Traditional Chinese Medicine (TCM) body patterns, like tongue and pulse readings, relate to how well targeted lung cancer drugs work. About 3000 people with a specific type of lung cancer will be followed for up to 5 years. Researchers will collect TCM inf…

This study uses artificial intelligence to analyze CT scans, pathology slides, and genetic reports from 1,000 lung cancer patients with EGFR mutations. The goal is to build a model that predicts how well targeted therapy will work after surgery. If successful, it could help docto…

This study looks at how a personalized strength training program affects people with different cancers, including lung, colon, breast, and blood cancers. 150 adults will either do supervised strength training plus home exercises, or just home exercises, for 12 weeks. Researchers …

This study looks at whether a blood test for circulating tumor DNA (ctDNA) can detect leftover cancer after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 participants will give blood samples before and after standard treatments. No new treat…

This study will use artificial intelligence and 3D CT scans to predict how well a person's lungs will work after different treatments for early-stage lung cancer. About 192 adults with stage IA non-small cell lung cancer will be followed for two years after surgery or a minimally…

This study watches for thinking and memory issues in 90 adults with early-stage, operable lung cancer. Researchers will track complaints like forgetfulness or trouble focusing before, during, and after treatment using simple questionnaires. The goal is to understand when these pr…

This study will measure specific immune cells in the blood of 200 non-small cell lung cancer patients before and after surgery. The goal is to see if these markers can help predict if the cancer will come back or how long patients will live. Participants must have early-stage lun…

This study looks at how opioid painkillers affect the success of immunotherapy in 100 people with advanced lung cancer who have moderate to severe pain. Researchers want to see if better pain control helps immunotherapy work better, and whether opioids themselves change the treat…

This study will collect blood samples from 620 adults with cancer (including lung cancer) to look for tiny markers released by tumors. Researchers want to see if these markers can help predict how well treatments work or when the cancer might come back. The study does not test a …

This study looks at 300 lung cancer patients who had immunotherapy before surgery but still had cancer cells left after the operation. Researchers will use advanced gene testing to find hidden genetic changes that might explain why the cancer didn't fully disappear. The goal is t…

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This observational study aims to understand how the immune system and tumor markers relate to treatment response in 500 people with advanced non-small cell lung cancer. Participants will provide tumor samples before and during immunochemotherapy. The study does not test any new d…